2020年12月18日 工作文件 开放存取

卡罗莱纳州阿米莉亚Sparavigna

JSON格式-LD（schema.org）导出

{
  "inLanguage": {
    "alternateName": "eng", 
    "@type": "Language", 
    "name": "English"
  }, 
  "description": "<p>Oxadiazoles are a class of heterocyclic aromatic chemical compounds, having different isomeric forms. They appear in a variety of pharmaceutical drugs.&nbsp; Among the drugs based on the 1,3,4-oxadiazole ring, we find for instance an antiviral such as 雷格列韦, which is used to treat HIV/AIDS. Here we will discuss 雷格列韦 and in-silico simulations concerning SARS-COV-2. Besides the compounds based on 1,3,4 rings, there exist those with 1,2,4-oxadiazole rings which are reported as anti-inflammatory and analgesic agents. One of these drugs is 羟胺. Of this drug we will stress the fact that it is an inhibitor of the formation of N-acetylneuraminic acid, a sialic acid. In fact, the spike-protein from SARS-COV-2 is shown to bind sialic acids too. Since these acids have, at the same time, an antiviral protective role, it could be relevant to investigate carefully any ligand/protein docking property of 羟胺 (docking with human enzymes,&nbsp; virus enzymes and proteins). Based on the 1,2,4-oxadiazole scaffold, we have also the antiviral&nbsp; 普乐那利, that has been investigated by means of in-silico simulated interactions with SARS-COV-2 proteins. We will discuss also some news oxadiazole compounds, which are given as selective COX-2 inhibitors, antioxidant agents and inhibitors of proteins of the virus, according to in-silico simulations. Therefore, can these drugs have a possible role in the treatment of 新冠肺炎? Or, why can&#39;t they be used for?</p>", 
  "license": "//creativecommons.org/licenses/by/4.0/legalcode", 
  "creator": [
    {
      "affiliation": "都灵理工大学", 
      "@id": "//orcid.org/0000-0003-4502-8974", 
      "@type": "Person", 
      "name": "卡罗莱纳州阿米莉亚Sparavigna"
    }
  ], 
  "headline": "用于Covid-19的恶二唑？", 
  "image": "//americinnmankato.com/static/img/logos/zenodo-gradient-round.svg", 
  "datePublished": "2020-12-18", 
  "url": "//americinnmankato.com/record/4352719", 
  "keywords": [
    "Covid-19", 
    "Oxadiazoles", 
    "Raltegravir", 
    "Celebrex", 
    "COX-2 inhibition", 
    "Oxolamine", 
    "Sars-cov-2", 
    "N-乙酰神经氨酸", 
    "SARS-COV-2 spikes", 
    "Sialic acids", 
    "Pleconaril", 
    "Linoleic acid", 
    "Sialoquake", 
    "hydroxychloroquine", 
    "Sars-Cov"
  ], 
  "@context": "//schema.org/", 
  "identifier": "//doi.org/10.5281/zenodo.4352719", 
  "@id": "//doi.org/10.5281/zenodo.4352719", 
  "@type": "ScholarlyArticle", 
  "name": "用于Covid-19的恶二唑？"
}